We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Amgen and Allergan will also compete against two other manufacturers to grab market share from Roche. Mylan and Biocon got their Herceptin biosimilar approved by the FDA in December 2017, followed ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Patients might not know about Roche Tissue Diagnostics, but the Arizona entity has been testing for cancer and helping devise ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

Roche Holding, a Swiss multinational pharmaceutical ... pharmaceuticals such as Valium and Tamiflu and cancer medications Herceptin and Avastin. That's in addition to its operations in diagnostics ...